
FDA Approves Sandoz Generic Option For Multiple Sclerosis
Sandoz announces U.S. FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis. Sandoz, a Novartis division, today announced the U.S. FDA approval and launch of Glatopa (glatiramer acetate injection) 40 mg/mL. Glatopa (glatiramer acetate injection) 40 mg/mL is FDA-approved as a fully-substitutable, AP-rated generic version of Copaxone* (glatiramer acetate injection)…